Table III.

Characteristics of HT in patients treated with regorafenib.

Hepatic toxicity	No. (%)a
Patients with liver metastasis prior to regorafenib treatment	19 (90.5)
Number of patients with HT	5 (23.5)
HT laboratory value alterations	4 (80.0)
Clinical signs only of HT	1 (20.0)
Median time to HT, months (range)	1.7 (0.9-11.2)
HT patients on hepatotoxic comedication	3 (14.3)
Liver progression at the time of HTb	1 (4.8)
Regorafenib continuation after HT	4 (19.0)
Reoccurrence of HT	0 (0.0)

^aUnless otherwise indicated.

^bLiver progression defined as new and/or larger tumor lesions within the liver on imaging. HT, hepatic toxicity.